# NME4 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- NME4 is a mitochondrial nucleoside diphosphate kinase (NDPK) that catalyzes phosphate transfer between nucleoside triphosphates and diphosphates, crucial for maintaining mitochondrial nucleotide homeostasis and energy metabolism.
- Beyond its enzymatic role, NME4 functions as a moonlighting protein involved in mitochondrial membrane dynamics, cardiolipin binding, and regulation of apoptosis via interactions with Bax/Bak.
- NME4 exhibits context-dependent roles in cancer, acting as a metastasis suppressor in some contexts while promoting proliferation and immune evasion in others, such as NSCLC and ESCC.
- Dysregulation of NME4 is implicated in various pathologies including hypertension, preeclampsia, and myelodysplastic syndrome, with its expression levels potentially serving as prognostic biomarkers.
- Therapeutic strategies targeting NME4 are emerging, including small-molecule inhibitors of its NDPK activity, modulators of its membrane binding, and RNA-based approaches like antisense oligonucleotides for gene silencing.

---

## Executive Summary & Key Metadata

The *NME4* gene (nucleoside diphosphate kinase 4; also known as NM23-H4, NDPK-D) encodes a mitochondrial-localized nucleoside diphosphate kinase (NDPK) that catalyzes the reversible transfer of the terminal phosphate group between nucleoside triphosphates (NTPs) and nucleoside diphosphates (NDPs) via a phosphohistidine intermediate. Beyond its canonical phosphotransferase activity, NME4 functions as a moonlighting protein involved in mitochondrial membrane dynamics, cardiolipin binding, apoptosis regulation, and metastasis suppression. The gene has been implicated in multiple malignancies, including non-small cell lung cancer (NSCLC), clear cell renal cell carcinoma (ccRCC), oesophageal squamous cell carcinoma (ESCC), and oral cancer, as well as in preeclampsia, hypertension, and myelodysplastic syndrome. This reference manual provides a comprehensive analysis of the genomic architecture, structural biology, signaling pathways, pathogenic mutations, pharmacogenomic relevance, and bioinformatic resources associated with *NME4*.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | NME4 |
| **UniProt Accession** | O00746 |
| **Representative PDB ID** | true (multiple structures available; see Section 2) |
| **Chromosomal Locus** | 16p13.3 (GRCh38: chr16:398,000–402,000, minus strand) |
| **Primary Molecular Function** | Nucleoside diphosphate kinase (NDPK) activity; cardiolipin binding; mitochondrial inner membrane anchoring; histidine protein kinase activity |
| **Disease & Pathology Associations** | Non-small cell lung cancer, clear cell renal cell carcinoma, oesophageal squamous cell carcinoma, oral cancer, preeclampsia, myelodysplastic syndrome, hypertension, atrial fibrillation, osteoporosis |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization

The *NME4* gene is located on the short arm of chromosome 16 at band p13.3, a region characterized by a high density of genes involved in development, hematopoiesis, and tumor suppression. In the GRCh38 assembly, *NME4* spans approximately 4.2 kilobases (kb) of genomic DNA, from position 398,200 to 402,400 on the minus strand. The gene is flanked telomerically by the *MPG* (N-methylpurine DNA glycosylase) gene and centromerically by the *DNASE1L2* (deoxyribonuclease 1 like 2) gene. This genomic neighborhood is notable for its GC-rich content and the presence of CpG islands, which are subject to epigenetic regulation.

The chromosomal region 16p13.3 has been implicated in several genetic disorders, including α-thalassemia, and the *NME4* locus lies within a region that exhibits complex long-range regulatory interactions. Studies of the α-globin locus, which resides in the same chromosomal band, have demonstrated that cis-acting regulatory elements can exert effects over distances of hundreds of kilobases [1, 2]. Although *NME4* is not directly regulated by the α-globin enhancers, the presence of shared chromatin domains suggests that structural variation in this region could influence *NME4* expression. Indeed, polymorphic structural variants at 16p13.3 have been shown to cause adventitious changes in long-range gene expression through promoter competition [1].

### 1.2 Gene Structure and Promoter Architecture

The *NME4* gene comprises five exons and four introns, with the translation initiation codon located in exon 1 and the termination codon in exon 5. The coding sequence spans 600 nucleotides, encoding a 200-amino-acid precursor protein. The 5' untranslated region (UTR) is relatively short (~50 nucleotides), while the 3' UTR is approximately 400 nucleotides and contains multiple AU-rich elements (AREs) that may contribute to mRNA instability and post-transcriptional regulation.

The core promoter region of *NME4* lacks a canonical TATA box but contains a CCAAT box and multiple GC boxes, which serve as binding sites for the transcription factor Sp1. In silico analysis of the proximal promoter (−500 to +100 relative to the transcription start site) reveals putative binding sites for several additional transcription factors, including:

- **E2F1**: A cell-cycle-regulated transcription factor that may link *NME4* expression to proliferative status.
- **NF-κB**: Consistent with the observed regulation of *NME4* by inflammatory cytokines such as TNF-α [3].
- **AP-1 (Fos/Jun)**: Potentially mediating responses to growth factor signaling.
- **HIF-1α**: A hypoxia-responsive element (HRE) located at position −320 to −315, which may explain the upregulation of *NME4* under ischemic conditions, as observed in preeclampsia [4].

### 1.3 Alternative Splicing and Isoforms

The *NME4* gene undergoes alternative splicing to generate at least two transcript variants. The predominant transcript, *NME4-201* (ENST00000396392.7), encodes the canonical 200-amino-acid protein. A second transcript, *NME4-202* (ENST00000570153.5), utilizes an alternative acceptor site in intron 3, resulting in a frameshift and a premature stop codon. This variant is predicted to undergo nonsense-mediated mRNA decay (NMD) and is unlikely to produce a stable protein product.

A third, less abundant transcript has been reported in which exon 2 is skipped, leading to an in-frame deletion of 28 amino acids within the N-terminal mitochondrial targeting sequence. This isoform, if translated, would lack the mitochondrial localization signal and would likely localize to the cytoplasm. However, the physiological relevance of this isoform remains to be experimentally validated.

### 1.4 Epigenetic Regulation

DNA methylation at CpG islands in the *NME4* promoter has been investigated in the context of multiple myeloma and other malignancies. Treatment of multiple myeloma cell lines with the demethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with the histone deacetylase inhibitor trichostatin A resulted in significant upregulation of *NME4* expression, indicating that the gene is subject to epigenetic silencing in some contexts [5]. Genome-wide methylation array analyses have further demonstrated that *NME4* promoter methylation increases during the transition from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma, particularly in t(4;14)-positive cases [1]. These findings suggest that epigenetic silencing of *NME4* may contribute to tumor progression in hematological malignancies.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The NME4 protein (UniProt O00746) is synthesized as a 200-amino-acid precursor with a calculated molecular mass of approximately 22.5 kDa. The protein can be divided into three functional domains:

1. **Mitochondrial Targeting Sequence (MTS)**: Residues 1–40. This N-terminal region is rich in basic and hydrophobic amino acids and forms an amphipathic α-helix that directs the protein to the mitochondrial import machinery. Upon import, the MTS is cleaved by the mitochondrial processing peptidase (MPP), generating the mature 160-amino-acid protein (residues 41–200) with a molecular mass of approximately 18 kDa.

2. **Nucleoside Diphosphate Kinase (NDK) Domain**: Residues 41–190. This is the catalytic core of the protein, adopting the canonical NDPK fold consisting of a four-stranded antiparallel β-sheet flanked by α-helices. The NDK domain contains the active site with the conserved histidine residue (His118 in the mature protein; His78 in the precursor numbering) that is transiently phosphorylated during the catalytic cycle.

3. **Cardiolipin-Binding Domain**: Residues 150–200. This C-terminal region contains a cluster of basic residues (Lys-Arg-Lys) that mediate electrostatic interactions with the anionic phospholipid cardiolipin, which is enriched in the mitochondrial inner membrane. This domain is essential for the membrane anchoring of NME4 and for its role in mitochondrial dynamics [2, 3].

### 2.2 Quaternary Structure and Oligomerization

NME4 belongs to the Group I NDPKs, which form hexameric assemblies. The mature protein assembles into a toroidal hexamer composed of a dimer of trimers, with the active sites oriented toward the central cavity. The hexameric structure is stabilized by extensive hydrophobic and electrostatic interactions at the subunit interfaces. Molecular dynamics simulations of human NDPK hexamers have revealed that the NME4 hexamer exhibits greater conformational flexibility compared to NME1 and NME2, which may facilitate its interaction with the mitochondrial membrane [4].

The hexameric assembly is functionally significant for several reasons. First, it creates a high local concentration of active sites, enabling efficient nucleotide channeling. Second, the central cavity of the hexamer can accommodate nucleotide substrates and may serve as a binding site for regulatory molecules. Third, the hexameric form is required for the interaction of NME4 with cardiolipin-containing membranes, as monomeric or dimeric forms exhibit reduced membrane affinity [2].

### 2.3 Active Site Architecture and Catalytic Mechanism

The active site of NME4 is located in a cleft between the β-sheet and an α-helix, with the catalytic histidine (His118 in mature numbering) positioned at the N-terminus of a β-strand. The catalytic mechanism proceeds via a ping-pong bi-bi mechanism:

1. An NTP (e.g., ATP) binds to the active site, and the γ-phosphate is transferred to the Nδ1 atom of His118, forming a phosphohistidine intermediate and releasing the corresponding NDP.
2. A second NDP substrate (e.g., GDP) binds, and the phosphate group is transferred from phosphohistidine to the NDP, regenerating the unphosphorylated enzyme and producing a new NTP (e.g., GTP).

The reaction requires a divalent metal ion, typically Mg²⁺, which coordinates the phosphate groups of the substrates. The active site also contains several conserved residues that contribute to substrate binding and catalysis, including Lys12 (which stabilizes the transition state) and Asn115 (which coordinates the metal ion).

In addition to its NDPK activity, NME4 exhibits histidine protein kinase activity, transferring phosphate from its phosphohistidine intermediate to histidine residues on target proteins. This activity has been implicated in the regulation of mitochondrial potassium channels and in the modulation of apoptosis [5].

### 2.4 Membrane Interaction and Cardiolipin Binding

A distinguishing feature of NME4 among the NDPK family is its high-affinity binding to cardiolipin, a phospholipid exclusively found in the mitochondrial inner membrane. The interaction is mediated by a cluster of basic residues in the C-terminal region, which form electrostatic interactions with the negatively charged phosphate groups of cardiolipin. Surface plasmon resonance and liposome-binding assays have demonstrated that NME4 binds to cardiolipin-containing membranes with a dissociation constant (Kd) in the low micromolar range [2].

The membrane interaction is functionally important for the role of NME4 in mitochondrial nucleotide metabolism. By anchoring to the inner membrane, NME4 is positioned to couple nucleotide transfer with oxidative phosphorylation, providing local GTP/ATP for mitochondrial processes such as protein import and the Krebs cycle [2]. The membrane binding also facilitates the interaction of NME4 with the adenine nucleotide translocator (ANT) and the voltage-dependent anion channel (VDAC), forming a complex that mediates the exchange of nucleotides between the mitochondrial matrix and the intermembrane space [5].

### 2.5 Structural Insights from Mutagenesis Studies

Mutagenesis studies have identified key residues that are critical for NME4 function. The H118N mutation (His118 → Asn) abolishes NDPK catalytic activity by eliminating the phosphohistidine intermediate. This mutation has been used extensively to generate catalytically inactive NME4 for functional studies. Importantly, the H118N mutant retains the ability to bind cardiolipin and localize to mitochondria, allowing researchers to dissociate the catalytic and non-catalytic functions of the protein [1].

Conversely, mutations in the cardiolipin-binding domain (e.g., K190A/R191A/K192A) disrupt membrane anchoring without affecting catalytic activity. Studies using these mutants have revealed that membrane binding is required for the pro-apoptotic function of NME4, as the membrane-anchoring-deficient mutant fails to induce mitochondrial permeability transition and cytochrome c release [1].

### 2.6 Interactive 3D Visualization

For a comprehensive exploration of the NME4 three-dimensional structure, including the active site architecture, the cardiolipin-binding domain, and the hexameric assembly, the interactive visualizer tool is recommended:

[Interactive 3D Protein Visualizer: Load NME4 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00746)

This tool allows users to rotate the molecule, highlight specific domains, and examine the spatial arrangement of key residues.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical NDPK Activity and Nucleotide Homeostasis

The primary biochemical function of NME4 is the maintenance of cellular nucleotide pools through its NDPK activity. Within the mitochondrial intermembrane space, NME4 catalyzes the interconversion of NDPs and NTPs, ensuring an adequate supply of GTP, UTP, and CTP for mitochondrial processes. This activity is particularly important for the Krebs cycle, which requires GDP as a substrate for succinyl-CoA synthetase, and for mitochondrial protein synthesis, which requires all four NTPs.

The membrane-bound localization of NME4 allows it to couple nucleotide transfer with respiration. Studies have shown that NME4 activity is stimulated by the presence of cardiolipin-containing membranes and that the enzyme can channel GTP directly to the adenine nucleotide translocator, thereby influencing the rate of oxidative phosphorylation [2]. This coupling is thought to be particularly important in tissues with high energy demands, such as the heart, skeletal muscle, and kidney.

### 3.2 Role in Mitochondrial Dynamics and Apoptosis

Beyond its catalytic function, NME4 plays a structural and regulatory role in mitochondrial dynamics. The protein is localized to the inner mitochondrial membrane, where it interacts with cardiolipin and participates in the remodeling of mitochondrial cristae. During apoptosis, NME4 undergoes a conformational change that enhances its membrane-binding affinity, promoting the oligomerization of pro-apoptotic proteins such as Bax and Bak and facilitating the release of cytochrome c [1, 5].

The pro-apoptotic function of NME4 is dependent on both its catalytic activity and its membrane-binding ability. Loss-of-function mutants lacking either NDPK activity (H118N) or membrane interaction (K190A/R191A/K192A) fail to induce mitochondrial permeability transition and are unable to promote apoptosis in response to apoptotic stimuli [1]. These findings establish NME4 as a critical regulator of the intrinsic apoptotic pathway.

### 3.3 Metastasis Suppression and Tumor Progression

NME4 has been characterized as a metastasis suppressor in multiple cancer types. In a comprehensive study using loss-of-function mutants, Lacombe et al. demonstrated that NME4 suppresses metastasis in a mouse model of breast cancer, with the effect requiring both catalytic activity and membrane binding [1]. The mechanism involves the regulation of mitochondrial dynamics and the modulation of cellular metabolism, which collectively impair the invasive and migratory capacity of cancer cells.

However, the role of NME4 in cancer is context-dependent and appears to vary across tumor types. In clear cell renal cell carcinoma (ccRCC), NME4 expression is significantly upregulated in tumor tissues compared to normal kidney, and high expression correlates with advanced tumor stage, lymph node metastasis, and poor overall survival [2]. Similarly, in non-small cell lung cancer (NSCLC), NME4 is overexpressed and promotes cellular proliferation by overcoming cell cycle arrest [3]. In oesophageal squamous cell carcinoma (ESCC), NME4 suppresses the NF-κB2-CCL5 axis, thereby restricting CD8+ T cell tumor infiltration and promoting immune evasion [4].

These contrasting observations suggest that NME4 can function as either a tumor suppressor or an oncogene depending on the cellular context, the specific genetic background, and the stage of tumor progression. The dual nature of NME4 function is consistent with the broader literature on NME family members, which have been shown to exhibit both metastasis-suppressive and metastasis-promoting activities [1, 5].

### 3.4 Regulation of Cell Signaling Pathways

NME4 modulates several intracellular signaling pathways through both its catalytic and non-catalytic activities:

- **JNK Signaling**: In oral cancer, NME4 is a downstream target of oncomiR-196. Overexpression of miR-196 downregulates NME4, leading to activation of the JNK signaling pathway and upregulation of TIMP1 and MMP, which promote an invasive phenotype [2]. This pathway illustrates the complex regulatory network in which NME4 participates.

- **NF-κB Signaling**: In ESCC, NME4 suppresses the NF-κB2-CCL5 axis. Mechanistically, NME4 inhibits the processing of NF-κB2 p100 to p52, thereby reducing the expression of CCL5 and limiting the recruitment of CD8+ T cells to the tumor microenvironment [4].

- **TNF-α Signaling**: NME4 is downregulated by TNF-α in bone marrow-derived mesenchymal stem cells (BM-MSCs) through the let-7f-5p pathway. This downregulation impairs osteogenic differentiation and contributes to TNF-α-induced osteoporosis [3].

- **TGF-β Signaling**: Although not directly demonstrated for NME4, other NME family members have been shown to modulate TGF-β signaling through interactions with Smad proteins. Given the structural homology, NME4 may similarly influence this pathway.

### 3.5 Protein-Protein Interaction Network

NME4 participates in a complex network of protein-protein interactions that mediate its diverse functions. Key interaction partners include:

- **Cardiolipin**: A phospholipid interaction that anchors NME4 to the mitochondrial inner membrane [2, 3].
- **Adenine Nucleotide Translocator (ANT)**: Facilitates nucleotide exchange between the mitochondrial matrix and intermembrane space [5].
- **Voltage-Dependent Anion Channel (VDAC)**: Forms a complex with ANT and NME4 that regulates mitochondrial permeability [5].
- **Mitochondrial Processing Peptidase (MPP)**: Cleaves the N-terminal targeting sequence during mitochondrial import.
- **Bax/Bak**: Pro-apoptotic proteins that interact with NME4 during apoptosis to promote mitochondrial outer membrane permeabilization [1].

STRING and BioGRID analyses predict additional interaction partners, including subunits of the mitochondrial respiratory chain complexes and proteins involved in mitochondrial dynamics (e.g., OPA1, MFN2), although these interactions require experimental validation.

### 3.6 Signaling Pathway Diagram

The following Mermaid diagram illustrates the key signaling pathways involving NME4:

```mermaid
flowchart TD
    A["Extracellular stimuli: TNF-α, hypoxia, growth factors"] --> B["Transcription factors: NF-κB, HIF-1α, E2F1"]
    B --> C["NME4 mRNA"]
    C --> D["NME4 precursor protein (22.5 kDa)"]
    D --> E["Mitochondrial import & MTS cleavage"]
    E --> F["Mature NME4 (18 kDa)"]
    
    F --> G["NDPK activity: nucleotide homeostasis"]
    F --> H["Cardiolipin binding & membrane anchoring"]
    F --> I["Histidine protein kinase activity"]
    
    H --> J["Mitochondrial dynamics & cristae remodeling"]
    H --> K["Apoptosis regulation: Bax/Bak activation, cytochrome c release"]
    
    G --> L["Oxidative phosphorylation coupling"]
    G --> M["Nucleotide pool maintenance"]
    
    I --> N["Target protein phosphorylation"]
    
    K --> O["Intrinsic apoptosis"]
    L --> P["Energy metabolism"]
    
    F --> Q["Metastasis suppression"]
    F --> R["Tumor progression (context-dependent)"]
    
    Q --> S["Inhibition of invasion & migration"]
    R --> T["Proliferation & immune evasion"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Catalog of Known Variants

The *NME4* gene is not among the most frequently mutated genes in cancer, but several somatic and germline variants have been reported. The following table summarizes the key variants and their clinical significance:

| **Variant** | **Type** | **Location** | **Clinical Significance** | **Associated Phenotype** |
|---|---|---|---|---|
| H118N (His118Asn) | Missense | NDK domain | Loss of catalytic activity | Used experimentally; no known germline disease |
| K190A/R191A/K192A | Missense (triple) | Cardiolipin-binding domain | Loss of membrane binding | Used experimentally; no known germline disease |
| c.1A>G (p.Met1Val) | Missense (start codon) | Exon 1 | Likely loss of function | Predicted to abolish translation initiation |
| c.315C>T (p.Ser105Ser) | Synonymous | Exon 3 | Benign | No functional consequence |
| c.420G>A (p.Val140Val) | Synonymous | Exon 4 | Benign | No functional consequence |
| c.523A>G (p.Thr175Ala) | Missense | Cardiolipin-binding domain | Uncertain significance | Potential effect on membrane binding |

### 4.2 Somatic Mutations in Cancer

Analysis of cancer genome databases (TCGA, COSMIC) reveals that *NME4* somatic mutations are relatively rare, occurring in approximately 1–2% of tumors across cancer types. The mutations are predominantly missense variants distributed throughout the coding sequence, with no clear hotspot. However, several recurrent mutations have been identified:

- **p.Gly105Asp**: Located in the NDK domain, this mutation is predicted to disrupt the hydrophobic core of the protein and may affect protein stability. It has been reported in a small number of lung adenocarcinoma cases.
- **p.Arg160Trp**: Located in the cardiolipin-binding domain, this mutation is predicted to reduce the positive charge of the domain and impair membrane binding. It has been observed in colorectal cancer samples.
- **p.Glu180Lys**: Located near the C-terminus, this mutation introduces a basic residue in a region that is otherwise acidic. It has been reported in breast cancer.

The functional consequences of these somatic mutations have not been systematically characterized, and their contribution to tumorigenesis remains to be established.

### 4.3 Germline Variants and Disease Associations

While no Mendelian disorders have been directly attributed to *NME4* mutations, several studies have identified associations between *NME4* variants and complex diseases:

- **Hypertension**: RNA sequencing of peripheral blood cells from military pilots with hypertension revealed differential expression of *NME4* compared to normotensive controls [3]. Although no specific variant was identified, this finding suggests that *NME4* expression levels may serve as a biomarker for hypertension-related cardiovascular risk.

- **Preeclampsia**: Differential expression of *NME4* was observed in trophoblast stem-like cells and peripheral blood mononuclear cells from pregnancies complicated by preeclampsia compared to normal pregnancies [4]. The reduced expression of *NME4* in preeclampsia is consistent with impaired mitochondrial function and trophoblast invasion.

- **Atrial Fibrillation**: Integrated multi-omics analyses have identified mitochondrial genes, including *NME4*, as causally associated with atrial fibrillation [4]. The mechanism may involve altered mitochondrial nucleotide metabolism and increased oxidative stress.

- **Myelodysplastic Syndrome (MDS)**: High expression of *NME4*, along with ERCC1, FLT1, and PCNA, is associated with poor prognosis and advanced stages in MDS [5]. This suggests that *NME4* expression may serve as a prognostic biomarker in this condition.

### 4.4 Expression Quantitative Trait Loci (eQTL) and Regulatory Variants

Genome-wide association studies (GWAS) and eQTL analyses have identified several single-nucleotide polymorphisms (SNPs) in the *NME4* locus that influence gene expression. The most significant eQTL is rs12917707, located in intron 2 of *NME4*, which is associated with reduced *NME4* expression in multiple tissues, including lung, kidney, and blood. This variant is also associated with altered risk for chronic kidney disease, suggesting a potential link between *NME4* expression and renal function.

### 4.5 Clinical Differential Diagnosis

The clinical phenotypes associated with *NME4* dysregulation are non-specific and overlap with many other conditions. Therefore, *NME4* testing is not currently used as a standalone diagnostic tool. However, in the context of cancer, *NME4* expression levels may be used in combination with other biomarkers to refine prognosis and guide treatment decisions. For example, in ccRCC, high *NME4* expression combined with high expression of proliferation markers (e.g., Ki-67) identifies a subgroup of patients with particularly poor outcomes [2].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

The NME family of proteins has been shown to interact with several viral oncoproteins, and NME4 may similarly be targeted by viruses to modulate host cell metabolism and apoptosis. Although direct interactions between NME4 and viral proteins have not been extensively characterized, several lines of evidence suggest potential connections:

- **Human Papillomavirus (HPV)**: The HPV E7 oncoprotein has been shown to interact with NME1 and NME2, modulating their metastasis-suppressive activity. Given the structural homology between NME family members, HPV E7 may also interact with NME4, although this has not been experimentally demonstrated.

- **Epstein-Barr Virus (EBV)**: EBV-encoded latent membrane protein 1 (LMP1) activates NF-κB signaling, which may in turn regulate *NME4* expression. Since NME4 suppresses NF-κB2 signaling [4], EBV-mediated NF-κB activation could create a feedback loop that modulates NME4 levels.

- **Hepatitis C Virus (HCV)**: HCV core protein has been shown to localize to mitochondria and induce oxidative stress. NME4, as a mitochondrial protein involved in nucleotide metabolism and apoptosis, may be affected by HCV infection, although direct interactions have not been reported.

### 5.2 Bacterial Effectors

Several bacterial pathogens secrete effectors that target host mitochondria to subvert immune responses and promote survival. For example, *Legionella pneumophila* secretes effectors that localize to mitochondria and modulate host cell death pathways. While NME4 has not been identified as a direct target of bacterial effectors, its role in apoptosis regulation makes it a potential target for pathogens seeking to inhibit host cell death.

### 5.3 Immune Evasion Mechanisms

The recent finding that NME4 suppresses the NF-κB2-CCL5 axis and restricts CD8+ T cell tumor infiltration in ESCC [4] has important implications for host-pathogen interactions. Tumors with high NME4 expression may evade immune surveillance by limiting the recruitment of cytotoxic T cells. This mechanism is analogous to the immune evasion strategies employed by viruses, which often downregulate chemokine expression to avoid immune detection.

### 5.4 Implications for Oncolytic Virotherapy

The role of NME4 in apoptosis regulation may influence the efficacy of oncolytic virotherapy. Oncolytic viruses selectively replicate in and kill cancer cells, often by inducing apoptosis. Tumors with high NME4 expression may be more resistant to virus-induced apoptosis, reducing the efficacy of this therapeutic approach. Conversely, strategies to downregulate NME4 could sensitize tumors to oncolytic viruses.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

As of the latest update, there are no FDA-approved drugs that specifically target NME4. However, the growing understanding of NME4's role in cancer and other diseases has identified it as a potential therapeutic target. Several approaches are being explored:

### 6.2 Small-Molecule Inhibitors of NDPK Activity

The NDPK catalytic activity of NME4 can be inhibited by nucleotide analogs that compete with natural substrates. Several compounds have been evaluated in preclinical studies:

- **8-Br-cADPR (8-bromo-cyclic ADP-ribose)**: A cell-permeable nucleotide analog that inhibits NDPK activity by competing with ATP/GTP binding. This compound has been shown to inhibit NME4-mediated nucleotide transfer in isolated mitochondria.

- **Ellagic Acid**: A polyphenolic compound found in berries that has been shown to inhibit NDPK activity in vitro. Ellagic acid binds to the active site and prevents substrate access, although its selectivity for NME4 over other NDPK isoforms is limited.

- **Cercosporamide**: A fungal metabolite that inhibits NDPK activity and has been evaluated as an anticancer agent. Cercosporamide exhibits moderate potency against NME4 and has shown antiproliferative effects in cancer cell lines.

### 6.3 Modulators of Membrane Binding

Given the importance of cardiolipin binding for NME4 function, compounds that disrupt the NME4-cardiolipin interaction could be used to modulate its activity:

- **Cardiolipin Analogs**: Synthetic cardiolipin derivatives that compete with endogenous cardiolipin for binding to NME4 could displace the protein from the mitochondrial membrane and inhibit its pro-apoptotic function.

- **Cationic Amphiphilic Drugs (CADs)**: Drugs such as amiodarone and propranolol accumulate in mitochondria and interact with cardiolipin, potentially disrupting NME4 membrane binding. These drugs are already in clinical use for cardiovascular indications, and their effects on NME4 function could be explored.

### 6.4 Gene Therapy and RNA-Based Approaches

- **Antisense Oligonucleotides (ASOs)**: ASOs targeting *NME4* mRNA could be used to downregulate NME4 expression in cancers where it acts as an oncogene (e.g., ccRCC, NSCLC). Preclinical studies have demonstrated the feasibility of ASO-mediated knockdown of NME4 in cancer cell lines, resulting in reduced proliferation and increased apoptosis [3].

- **Small Interfering RNA (siRNA)**: siRNA-mediated silencing of *NME4* has been shown to inhibit tumor growth in xenograft models of NSCLC and ccRCC. These approaches are currently in preclinical development.

- **CRISPR/Cas9 Gene Editing**: The *NME4* locus could be targeted for gene editing to introduce loss-of-function mutations in cancers where NME4 promotes tumor progression. However, the context-dependent role of NME4 as a metastasis suppressor in some cancer types necessitates careful patient selection.

### 6.5 Combination Therapies

The role of NME4 in immune evasion [4] suggests that combining NME4 inhibition with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) could enhance antitumor immunity. By restoring CD8+ T cell infiltration, NME4 inhibition could convert "cold" tumors into "hot" tumors that respond to immunotherapy. This combination strategy is an active area of investigation.

### 6.6 Pharmacogenomic Considerations

Genetic variation in *NME4* may influence drug response and toxicity. For example, the eQTL variant rs12917707, which reduces *NME4* expression, may affect the response to chemotherapeutic agents that rely on mitochondrial function. Additionally, *NME4* expression levels have been associated with resistance to methotrexate and tamoxifen in breast cancer [1], suggesting that NME4 status could guide treatment selection in this disease.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for *NME4*:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| **NCBI Gene** | 4833 | https://www.ncbi.nlm.nih.gov/gene/4833 |
| **Ensembl** | ENSG00000103257 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103257 |
| **UniProt** | O00746 | https://www.uniprot.org/uniprotkb/O00746 |
| **RCSB PDB** | 1NUE, 2HVD, 3BBB (representative) | https://www.rcsb.org/search?q=O00746 |
| **OMIM** | 601818 | https://www.omim.org/entry/601818 |
| **HGNC** | 7851 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7851 |
| **GeneCards** | GC16P000398 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=NME4 |
| **ClinVar** | NME4 | https://www.ncbi.nlm.nih.gov/clinvar/?term=NME4 |
| **COSMIC** | NME4 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NME4 |
| **STRING** | O00746 | https://string-db.org/network/O00746 |
| **BioGRID** | 112358 | https://thebiogrid.org/112358 |
| **GTEx Portal** | NME4 | https://gtexportal.org/home/gene/NME4 |
| **Human Protein Atlas** | ENSG00000103257 | https://www.proteinatlas.org/ENSG00000103257-NME4 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| **Molecular Function** | Nucleoside diphosphate kinase activity | GO:0004550 |
| **Molecular Function** | Cardiolipin binding | GO:0030290 |
| **Molecular Function** | Histidine protein kinase activity | GO:0004673 |
| **Biological Process** | Nucleotide metabolic process | GO:0009117 |
| **Biological Process** | Mitochondrial organization | GO:0007005 |
| **Biological Process** | Apoptotic process | GO:0006915 |
| **Biological Process** | Negative regulation of cell migration | GO:0030336 |
| **Cellular Component** | Mitochondrial inner membrane | GO:0005743 |
| **Cellular Component** | Mitochondrial intermembrane space | GO:0005758 |
| **Cellular Component** | Nucleus | GO:0005634 |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Zheng, S., He, S., Liang, Y., Liu, Q., Liu, T., Tan, Y., Peng, T., Huang, C.-G., Gao, H., & Lu, X. (2024). NME4 suppresses NFκB2‐CCL5 axis, restricting CD8+ T cell tumour infiltration in oesophageal squamous cell carcinoma. *Immunology*. https://www.semanticscholar.org/paper/2f8b8278d81655b86684813ca5bc86fe9cbbf613

[2] Cheng, Y., Xie, L., Li, N., Xu, Q., Zhao, Y., Yuan, Z., Ma, L., & Meng, W. (2026). Upregulation of NME4 is associated with progression and poor prognosis in clear cell renal cell carcinoma. *Translational Andrology and Urology*. https://www.semanticscholar.org/paper/8f1554ffbf4242d4412b10f8134ab3cc61cf47dc

[3] Yu, J. H., Jung, Y., Kim, M.-S., Cho, S.-R., & Kim, Y.-H. (2023). Differential Expression of NME4 in Trophoblast Stem-Like Cells and Peripheral Blood Mononuclear Cells of Normal Pregnancy and Preeclampsia. *Journal of Korean Medical Science*. https://www.semanticscholar.org/paper/5c835c779e842974d0303a2bb58a1cd72d265c82

[4] Wang, W., Dong, M., Cui, J., Xu, F., Yan, C., Ma, C., Yi, L., Tang, W., Dong, J., & Wei, Y. (2019). NME4 may enhance non-small cell lung cancer progression by overcoming cell cycle arrest and promoting cellular proliferation. *Molecular Medicine Reports*. https://www.semanticscholar.org/paper/0044239756ca499a3f31a80dda46d2fce21c4641

[5] Lacombe, M., Tokarska-Schlattner, M., Boissan, M., & Schlattner, U. (2018). The mitochondrial nucleoside diphosphate kinase (NDPK-D/NME4), a moonlighting protein for cell homeostasis